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Abstract
Introduction: Hepatitis C virus (HCV) represents a serious public health concern. People who inject drugs (PWID) are at
particular risk and nearly half (45%) of PWID in England may be infected. HCV prevention interventions have only had
moderate impact on the prevalence of HCV in this population. Using qualitative methods, we sought to detail the protective
practices potentially linked to HCV avoidance among PWID, and explore the motivations for these.
Methods: The study used a life history approach allowing participants to detail their lived experience both before and
during the course of their injecting careers. Thirty-seven participants were recruited from drug services in London, and from
referrals within local injecting networks. A baseline and follow-up in-depth qualitative interview was carried out with each
participant, and for half, a third interview was also undertaken. All underwent testing for HCV antibody. Analyses focused on
developing a descriptive typology of protective practices potentially linked to HCV avoidance.
Results: Practices were deemed to be protective against HCV if they could be expected a priori to reduce the number of
overall injections and/or the number of injections using shared injecting equipment. Participants reported engaging in
various protective practices which fell into three categories identified through thematic analysis: principles about injecting,
preparedness, and flexibility.
Conclusions: All participants engaged in protective practices irrespective of serostatus. It is important to consider the
relative importance of different motivations framing protective practices in order to formulate harm reduction interventions
which appeal to the situated concerns of PWID, especially given that these protective practices may also help protect
against HIV and other blood borne infections.
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Introduction
Approximately 216, 000 individuals in the UK are living with
chronic hepatitis C virus (HCV). [1] Regional estimates suggest
that, in England, 45% of people who inject drugs (PWID) are
living with chronic HCV. [1] The prevalence estimates for PWID
in Wales (39%), Northern Ireland (29%), and Scotland (55%) are
also high. [1] HCV-related admissions to hospital have risen
threefold (from 612 in 1998 to 1, 979 in 2010), as have HCV-
related deaths (from 98 in 1996 to 323 in 2010). [1] In London the
prevalence of HCV among PWID is 56% (CI 51%–62%) and
among former PWID, 39% (CI 33%–46%). [1].
The strongest predictor of HCV infection is a history of
injection drug use. [1,2] A recent study has suggested that 85% of
those with chronic HCV infection are either current or former
PWID. [2] Specific risk factors for HCV exposure among PWID
include: sharing needles, sharing other injection equipment (e.g.
cookers and filters [3,4]), frequency of injection [5], front loading
[6], being injected by another [7], injection cocaine use [8], lack of
treatment for dependence [5,9], being female (though the
prevalence of HCV in England and Wales is higher in males
[2]) [7], and the length of time since first injection. [5,8,10]
Structural factors, such as incarceration [9,11] and homelessness
[12], have also been correlated with HCV seropositivity.
Annual reports produced by the UK Health Protection Agency
emphasise the prevention of new infections as a priority. [1,13]
Opiate substitution therapy and needle exchange programmes are
the most common primary prevention methods aimed at reducing
transmission of HCV. Though needle exchange programmes
(NEP) have been shown to reduce the incidence of HCV, opioid
substitution treatment (OST) has only demonstrated marginal
effectiveness.[14–16] However, evidence from the Amsterdam
Cohort Studies suggests that full participation in harm reduction
programmes (defined as participating in NEP and OST concur-
rently) is associated with a decrease in incident HCV infections
when compared to no participation (incidence rate ratio 0.43
[95% CI 0.21–0.97]). [17].
Other prevention strategies include behavioural programmes
and syringe bleaching, neither of which have produced convincing
results. [14] A 2009 study assessing the efficacy of a series of
motivational interventions aimed specifically at raising awareness
of behaviours which put PWID at risk of HCV (with the explicit
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goal of avoiding HCV seroconversion) showed no effect when
compared to the control population. [18] Thus, with the exception
of needle exchange programmes, and the marginal efficacy of
OST, the remaining policy interventions have been ineffectual in
reducing exposure, and subsequent seroconversion, to HCV. [14]
Needle exchange programmes, whilst effective in reducing
incident infections, have had little impact on the overall
prevalence. [14] This is despite these harm reduction strategies
being proven effective for reducing HIV infection. [19].
Several qualitative studies have suggested that the inefficacy of
the interventions to prevent HCV rests not on their inability to
reach the target population, or their inability to offer sound
strategies to avoid infection, but rather on failure to recognise the
weak motivational force of HCV avoidance.[20–22] Despite the
fact that current guidance for drug treatment providers in the UK
emphasises strategies to help PWID avoid HCV infection [23], this
approach is unlikely to result in a significant decrease in incident
infections; therefore, it is clearly of interest to policy makers to
discover those practices that are likely to facilitate HCV
avoidance, what motivations are responsible for such practices,
and what circumstances frustrate these practices.
We report on a qualitative study which sought to understand the
drug use and social practices associated with long-term viral
avoidance, and to consider how such practices are shaped by the
life trajectories of PWID, and their social contexts over time. The
study was innovative through its use of life history methods to
understand and detail the lived experience of people who have
been injecting long-term. It offers to inform our understanding of
practices that have protective potential with respect to HCV.
What follows is a typology of protective practices identified across
the interview accounts of the 37 PWID who participated in the
study. We also explore the motivations and interpretative
frameworks shaping these practices, and how they may offer a
putative protective advantage against HCV infection.
Methods
Participants
Participants were referred from collaborating HCV testing and
screening services in South East and North London. At each
recruitment location a Primary Care Physician contacted eligible
participants to pass on both the participant information sheet and
the contact details of a member of the research team. Participants
were also recruited through referral within drug user networks.
Purposive sampling was employed in order to elicit the participa-
tion of both male and female PWID who experienced differing:
durations of injection drug use, housing situations, injection drug
preferences (i.e. heroin, crack cocaine, and ‘speedballs’), and (in the
case of HCV positive participants) the length of time since HCV
diagnosis. This sampling strategy resulted in the inclusion of
participants of different ages, ethnic backgrounds, and relationship
status. Those included in the sample also had varying experiences
regarding: incarceration, preferred injection location (e.g. groin),
therapeutic methadone use, and inpatient drug treatment.
The sample included 37 individuals, all of whom were invited
for a second interview. A third interview was requested of half
those attending the second interview. All participants were
articulate and able to describe in great detail their injection
practices, their motivations for engaging in such practices, and the
conditions under which these practices are frustrated.
Data Collection
Data were collected between January 2010 and August 2011 by
the principal investigators (MH and TR). All participants
consented to an initial in-depth interview lasting approximately
two hours. This baseline interview was designed around a life
history approach and entailed the creation of life-grids to map
participants’ life trajectories. [24] The creation of the life-grids was
participant-led. Most participants focused on significant life events,
and ongoing experiences with injection drug use. Timeline
MakerTM software was used to create visual representations of
the life-grids and to facilitate case comparisons revealing potential
relationships between life events and patterns of injection
practices, risk avoidance, and those factors which facilitate risk.
Following the initial interview participants were invited to
submit to serological screening for HCV. Once they had
completed HCV testing, participants were invited for a second
interview. Interviewers were informed of the test results prior to
the second interview. These follow-up interviews pursued key
narrative themes identified in the first interview while focusing
across cases to explore: the development of risk aversion, the
perceived constraints to risk avoidance presented by particular
conditions or situations, and the properties and dimensions of
prophylactic drug use practices in context and over time. A third
interview was conducted as a means to further pursue participant
narratives deemed to be particularly information-rich.
Data Analysis
All interviews were audio recorded (with participant consent)
and transcribed. Drawing across life history and qualitative
interview data, both within and across cases, our analysis reported
here focused primarily on systematically identifying a descriptive
typology of protective practices potentially linked to the avoidance
of HCV in the long-term. Interviews were coded as they were
collected in order to inform the direction of subsequent interviews.
Coding was carried out by two members of the research team.
Codes were compared between researchers and points of
divergence were discussed at length in order to maximise internal
reliability. Drawing upon inductive and grounded analysis
techniques, we also coded accounts for key themes linked to
practices potentially HCV-protective in order to explore partic-
ipant interpretative frameworks and the motivations shaping these.
Protective practices fell broadly into three categories: principles,
preparedness, and flexibility concerning drug use.
Ethics Statement
Ethical approval for the study was obtained from the Research
Ethics Committee at the London School of Hygiene & Tropical
Medicine and the North London Regional Ethics Committee. The
recruitment materials explicitly indicated that participation in the
study was voluntary, anonymous, and that the results of the
serological screening would be confidential. A separate consent
form was issued to participants who agreed to undergo serological
screening for HCV antibodies, and HCV RNA. All participants
provided written consent to be interviewed, and to participate in
HCV screening. Counselling services were provided at the
participating HCV testing centres to inform participants of the
results and to answer questions.
Results
Twenty-seven of the participants (73%) were men and 10 (27%)
were women. All of the participants were long-term users (defined
as having injected for six years or longer). The average age of
participants was 41 years (23–57 years). Twenty-five participants
(68%) had spent time in prison, 20 (54%) had been previously
admitted to a rehabilitation or detoxification facility, 35 (95%)
were either receiving OST at the time of the interview or had at
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some point in the past, and 33 (89%) were either on a break from
injecting or had taken breaks from injecting in the past.
All 37 participants underwent testing for HCV, with 22 (59%)
testing seronegative, and 15 (41%) seropositive. Many of those
who were found to be HCV-positive were consistently and
conscientiously engaging in practices deemed theoretically protec-
tive. Practices were deemed protective if they could be expected to
reduce the total number of injections (e.g. when reverting to
smoking/snorting rather than injecting), or when the practice
limited or eliminated injections using shared equipment (e.g.
separating or marking of equipment or having rules about not
sharing needles/syringes). Participants often reported engaging in
several different protective practices.
A Typology of HCV Protective Practices
The protective practices identified across participant interview
accounts fell broadly into three distinct, but related, thematic
categories: principles, preparedness, and flexibility concerning the
enactment of drug use practices. We defined the category
‘principles’ to include those normative practices which were
routinely and often rigidly adhered to by participants. Principles
were most often described prescriptively (e.g. ‘‘I actually had rules,
it was [to] use clean needles…clear up after yourself…always’’
[C05]); though proscriptive principles were not uncommon (e.g.
‘‘I’m not sharing needles! - blatant, I’m not sharing. If it hurts your
feelings, well tough, I’m not sharing’’ [C04]). Principles did not
have to be inspired by specific motivations and could be described
axiomatically (e.g. ‘‘I don’t know, there’s just something about me,
I wouldn’t use other people’s filters’’ [L04]). We defined the
category ‘preparedness’ to include any purposive act which was
carried out based on a clear understanding of foreseeable
circumstances, and the express desire to mitigate or avoid risks
associated with such circumstances (e.g. ‘‘There’s always been some
kind of back-up, whether it’s been a bag of morphine pills or
methadone or gear…I rarely, rarely let myself get sick’’ [I02]).
Lastly, ‘flexibility’ was defined as resilience, or adaptability,
particularly when practices were adapted or abandoned in the
face of either imminent or future risk (e.g. ‘‘Even if I’m
withdrawing really badly I would never share a work, I’d put it
on a bit of foil [to smoke] – I would never, ever take someone’s
works’’ [C04]). We outline below the protective practices falling
within these three categories.
Principles
Rules about not sharing injecting equipment, and/or the
disposal of needles/syringes. Of the 37 participants 13 (35%)
described having rules about not sharing injecting equipment or
about disposing of needles/syringes. Among these 13 participants,
rules included: never sharing filters (N = 4, 31%), not sharing
needles/syringes (N = 4, 31%) or always using clean needles/
syringes (N = 3, 23%), putting only one person’s sharps in the
sharps container (N = 3, 23%), bending or snapping off the tip of
the needle/syringe after use (N = 2, 15%), and not opening the
sharps container to retrieve needles/syringes (N = 1, 8%).
Being in charge of mixing drugs and/or distributing the
drug mix. Three (8%) of the 37 participants reported always
being in charge of mixing drugs (i.e. the preparation of drugs to
render them suitable to inject, generally by dissolving powdered
heroin into citric acid or vitamin C), or the distribution of drugs
among other PWID once they had been mixed.
Separation and/or marking of injecting equipment. Of
the 37 participants in the study 17 (46%) described separating or
marking their injecting equipment. Separating equipment includ-
ed: meticulously allocating separate equipment for each user
including a needle/syringe disposal bin in case it became necessary
to re-use needles/syringes, hiding or locking up injecting
equipment in the home, or injecting in different rooms in order
to keep equipment separate. Marking included: burning needles/
syringes, marking wrappers with initials, and habitually disposing
of needles/syringes such that they could be identified if it became
necessary to re-use (e.g. one partner habitually replaces the cap,
while the other does not). The use of NevershareTM syringes also
indicated a desire to distinguish equipment as they are sold in
multiple colours for the express purpose of reducing the risk of
accidental sharing. [25] Separating equipment was practised by 10
(59%) of the 17 participants, four (24%) reported marking their
equipment, and three (18%) both separated and marked their
equipment.
Using drugs alone or at home. Of the 37 participants 23
(62%) reported a preference for using drugs alone or at home.
Most participants described drug use alone or at home as a strong
preference. Heroin was described by several participants as a drug
best used alone, or as an anti-social experience, unlike using crack
cocaine or marijuana which was described as a group, or a social
activity.
Preparedness
Stockpiling methadone/buprenorphine. Of the 37 par-
ticipants, 11 (30%) described stockpiling methadone and/or
buprenorphine (SubutexH). All 11 participants reported stockpiling
methadone; two of these participants also reported stockpiling
buprenorphine.
Carrying or stashing injecting equipment. Nearly half of
the 37 participants (N = 17, 46%) reported always carrying
injecting equipment and/or stashing needles/syringes. Of these
17 participants, 14 (82%) reported stockpiling clean needles/
syringes, while nine participants (53%) reported always carrying
injecting equipment.
Flexibility
Temporary heroin smoking/snorting. Twenty-four (65%)
of the 37 participants described having smoked/snorted heroin
temporarily and as an alternative to injecting. For many
participants smoking/snorting constituted their first experience
using heroin; all went on to inject regularly, and the length of time
participants smoked/snorted prior to injecting ranged from hours
to 10 years. Several justifications for smoking heroin were often
referenced by the same individual. Some participants smoked/
snorted and injected concurrently.
The Lived Context of Protection
Principles. Several key themes were identified from the
narratives surrounding injecting principles. Factors which inspired
routine and rigidly adhered to practices included: concerns about
hygiene, personal responsibility, image management, injecting
pragmatics, and risk management. Principles were often described
as very personal commitments motivated by sensibilities developed
in childhood; these included powerfully motivating concerns for
hygiene, and notions of personal responsibility.
Concerns about hygiene were often described as transcendent,
and did not apply specifically to drug use. Within the context of
injection drug use, however, concerns for hygiene were primarily
manifest as both an unwillingness to share syringes and/or other
injecting equipment, and having strict rules about the disposal of
syringes.
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I’ve never knowingly shared works, but I have shared spoons
and stuff and I know that’s an issue, but a lot of people I
know that do share works, you know, wouldn’t dream of
wearing somebody else’s fucking underwear or wearing
somebody else’s socks, I’m just really squeamish about
sharing works, I just find it horrible, the idea of it creeps me
out. There’s something really personal about blood anyway
and, apart from that, my mother was a nurse and I’ve got all
my hang-ups about germs and stuff… [L16].
Notions of personal responsibility were often described in terms
of responsibility to children or other close family members, though
responsibility to other PWID was not uncommon.
Yeah, well there was rules, you want to come round, you
make sure you clean up yourself and put it in the [sharps
container]. I have a child…I have a nephew, he’s two years
old, he’ll come walking around, you know what I mean?
[C05].
Image management was another motivation for adherence to
strict principles and was largely framed as a desire to avoid visible
signs of drug use (particularly with respect to injection site
infections), and to maintain a ‘normal’ looking image. This
normalcy was described as important when it came to hiding drug
use and avoiding negative attention and, often, stigmatisation at
the hands of non-users (including hospital/clinic staff), and other
PWID.
[I was smoking because] I didn’t like the marks all the time.
It was difficult, like when I had relationships, like I’d show
them the marks. I used to like going swimming and those
marks are very hard to hide. So like I say, [I smoke] off and
on, when I’ve been on my own I start using more, inject
more than when I’m with a relationship or I have something
going, so that’s what I’m saying. [I01].
Injecting pragmatics primarily involved concerns over vein care.
Damaged or collapsed veins were a major concern as they resulted
in lengthy and sometimes painful injecting experiences, and would
often result in participants resorting to injecting veins that posed
increased danger or discomfort (e.g. neck, groin).
Ah, I don’t really know anyone else who bends the tips [of
used syringes] over. Why did I start doing that? I’ve been
doing it for a long time…to stop myself using them again.
To stop myself using them when they’re blunt really. To
force myself to use a new one, you know. ’Cause it might
look sharp, but I mean you know, it’s not sharp you know,
and you’re scraping it to try and get it sharp and putting
burs on it and you rip your veins up and everything like that,
you know, so. It’s just, it’s just a safety thing, you know, to
stop me using it and to stop anyone else using it as well. So
no one else can use my, even my old ones. [I04].
Risk management was a common motivation for strict
adherence to principles. The most common motivation was
avoidance of HIV, though HCV and nondescript pathogens (e.g.
‘‘germs’’, ‘‘diseases’’, ‘‘the bug’’) were also frequently mentioned.
Well yeah, the Hep-C is always a concern, but being heavily
drugged a lot of the time things aren’t…things go out the
window but, you know, the things you do you stick to, like
clean [equipment], they’re just things you stick to. [L13].
Injection site infections were also a concern. Participants often
described their injecting principles as having developed in
response to family, friends, or injecting partners who had become
ill – the physical, outward manifestations of illness were often
explicitly referenced.
[My mother] had a big abscess and it even started going in
to the, eating in to the bone, it was a big abscess…big
abscess, and yeah, she had half her leg missing. My brother
used to skin pop because he was diabetic and he was doing
the gear as well, and he used to skin pop in his arm with his
insulin and his gear, and he got an infection, I can’t
remember, it was about 20 letters long…I’ve never shared,
never, never shared a needle or a spoon in my life, if I share
a needle, not a needle, a spoon, I’ll always make sure I draw
it up first, know what I mean, and I make sure it’s all fresh
stuff in there and I draw it up first, and then [someone else]
can draw it second…I’ve never, never shared needles, no,
never, or equipment, never, no, no. [C04].
No, because I never shared anything - or maybe I must have
used J’s or one of the girls’ once - but other people’s, I don’t
think I used other people’s, or if I did I washed it, because
we used to wash, wash it out, because I never could use
other people’s needles. And plus another thing, and plus I
think it’s the yellow jaundice as well, because people used to
go, because a couple of them used to go yellow, I says, ‘woo,
why?’, right, and I think that’s what it really was because
people used to get yellow jaundice from sharing needles and
they used to get, some had blood poisoning and I think I just
used to get frightened of getting disease germs. [L10].
Occasionally, participants were unable to describe their rigid
adherence to certain principles, claiming that:
…it’s weird. I suppose, I was so used to [not sharing] that I
just kept on doing it. And I suppose I wouldn’t have cared to
have [to] share if I thought about it. But I was so used to
doing it that I just…I kept on doing it. [L14].
Preparedness. Preparedness, in the form of stockpiling
methadone/buprenorphine, or carrying or stashing injecting
equipment, was commonly referred to as a principle or rule.
Understanding contingencies, knowing ‘how it worked’, being
organised, and anticipating need (particularly with respect to the
need to inject upon waking in the morning) were all common
themes among participants who reported having principles which
involved preparedness. Anticipating need was occasionally de-
scribed with considerable gravity; often with respect to the practice
of stockpiling methadone/buprenorphine ‘‘in case of an emer-
gency’’ [C01].
I didn’t want to catch any diseases…it just seemed to me
logic that if syringes were free and they were in a clear label,
which they were, there was no need really not to have
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them…you think ahead. That is just the way it worked for
me. [I02].
I travelled a lot…but I always made sure I had clean
syringes, or if I was going to be out on the road I made sure I
had methadone if I knew that I like – you know what I’m
saying, so, thank goodness I was never put in the position
where I was really, really sick with heroin and no syringes.
[I03].
Because he always had his, we always made sure we had
enough of everything, we always made sure we had enough
pins, enough citric, enough steri-wipes, enough of everything
so that we never ran out, we used to have a little drawer full
of pins and steri-wipes and citric and whenever we ran out
we used to just go to the drawer and pick them up and fill
our little bum bags back up again, it wasn’t…yeah, we’d
always have equipment, always, always…we always used to
get the equipment first, we always made sure we had
equipment before we bought the drugs, that was, that’s a
stupid thing to do is buy a drug if you haven’t got the
equipment… if you’re going to take drugs organise man,
make sure you’ve got your tools before you buy your drugs
because it’s stupid…or smoke it if you haven’t got the tools,
smoke it, simple, improvise, snort it. [L03].
Flexibility. Participants frequently described factors which
disrupted protective practices. These factors were variously
described as individual (e.g. a traumatic life event), situational
(e.g. disruption of drug supply, exposure to risk-encouraging social
networks, external threats to safety and/or security), and structural
(e.g. barriers to accessing clean needles or foil, methadone
distribution policy, obtrusive policing policy/practice). Often,
despite the most assiduous planning and preparation, factors
beyond the control of the participant frustrated protective
practices. Despite this, many users were able to navigate such
disruptions. The majority of the accounts of flexibility described
finding other routes of administration when it was not deemed safe
or desirable to inject. Participants reported smoking and/or
snorting (and, in one case, taking heroin orally) when: in the
company of people they did not know or trust, there was no access
to clean/sharp syringes, or when injecting equipment other than
syringes was being shared. The most common accounts detailed
circumstances in which there was no access to clean/sharp needles
and it became necessary to smoke or snort instead.
So I was waiting and waiting, I had the gear [in jail] and was
waiting for hours and hours, and then I had to wait even ’till
the next day because it was twenty-four hour [lock-up]. In
the end they send it with the guy that was coming knocking
on the door giving you a cup of tea in the evening. He had
the [syringes] but [they were] used. And I’ve been waiting a
day and a half already, and I say, ‘just take it back’. So I
snorted it instead. [L14].
Additionally, participants claimed that being able to wait or
abstain from using drugs was an effective strategy to avoid
injecting in situations deemed risky.
If it was a choice between rummaging through a sharps bin
that was just, you know, in a room that I’d never been in
before in me life, and I show up in there with people I’d
never met before in me life, I’d just take my gear and
go…I’d fucking take my gear and go home. You know, I’ve
walked like bloody eight miles, you know, eight miles just to
score and [then have come] back… [I04].
Despite the fact that finding other routes of administration and
being able to wait or abstain is likely prophylactic, the motivation
for resorting to such measures was not always out of concern for
contracting HIV or HCV. Participants frequently described
smoking heroin to avoid: the dangers of injecting into the neck
or groin, skin infections, and to avoid injuring veins.
But in the end you just end up saying, ‘well look, you know, you
look a mess’, yeah you know, when you’re trying to get a vein
in your hands and everything, mine are so much better now
you wouldn’t believe, yeah. But I looked like a dart board
honestly, I really did, it was horrible, you know, and um, I
just started to smoke it, I just had to smoke more of it and
that’s what I done. [L09].
Discussion
We have used a qualitative life history approach to generate rich
accounts of the protective strategies and associated motivations of
PWID. This generated a descriptive typology of practices
potentially protective against HCV contextualised by three
distinct, but overlapping, strategic frameworks for action: principles
framing normative practices in relation to minimising risk linked to
injecting, an orientation towards preparedness and contingency
planning to avoid disruption to risk management, and the capacity
for flexibility to adapt when disruptions to normative practices or
intentions occur. A life history approach enabled participants to
narrate significant events in their lives, as well as to describe
practices in relation to injecting and HCV, in time as well as in
context. As a result, it becomes possible to establish roughly when
motivations (and their associated practices) came into force,
including how HCV-protective practices may have motivational
antecedents unrelated directly to injecting (such as in the case of
ideas around hygiene underpinning rules regarding not sharing).
The life history methodology established that many practices were
long-standing and remained consistent throughout the partici-
pant’s lifetime. Crucially, we find that many motivations
surrounding practices which are potentially HCV-protective are
indirectly rather than directly related to HCV, including situated
concerns regarding hygiene, personal responsibility, image man-
agement, and maximising the pragmatics and pleasures of
injecting.
Life history approaches have been used as a means to minimise
recall bias in studies of patients suffering from chronic respiratory
disease [26], and as a clinical tool to identify childhood
maladaptations in patients undergoing psychodynamic psycho-
therapy. [27] Though life history approaches have been used in
the field of addiction studies, it is often the case that life histories
are elicited for the period after which dependent drug use has
commenced. However, lengthy retrospective accounts commenc-
ing at the time of birth or early childhood have been used in
addiction studies to identify and contextualise critical events in the
lives of female crack users in Ohio [28], to identify the causal
relationship between childhood experiences and heroin injection
[29], and to highlight circumstances which might have been
amenable to early intervention in deceased PWID in Scotland.
[30] Here, we see the generation of life histories to prevent the
narrowing of research focus specifically around risk as it relates to
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HCV, and to instead open up an understanding of how HCV risk,
and its reduction, is lived in context. This gives rise to appreciating
how motivations beyond the specifics of viral risk – such as
preventing stigma by looking ‘normal’, or preventing painful
injection by preserving veins through not using previously used
needles, nonetheless have HCV-preventive potential. [21].
Relatively infrequent mention of HCV suggests that its
avoidance may act as weak motivation for the multiple protective
practices reported by participants. This could imply that HCV is
not well understood in terms of behavioural prophylaxis, or that
HCV avoidance is competing with other, often more immediate,
motivations. The former possibility is contrary to the conclusion of
Carruthers [31]; however, two studies among PWID in New York
City reported that, though HIV avoidance was a primary
motivator for engaging in strategies, practices and prevention
tactics, relatively few participants (one out of 25) had extensive
knowledge about HCV [32] and, among participants who did not
have extensive knowledge, there were many misconceptions about
transmissions, symptoms, long-term effects, and treatment. [33]
The suggestion that HCV transmission is, in fact, well understood
among PWID but that it is competing with more proximal
concerns (e.g. risk of arrest, overdose, withdrawal) has been
proposed by Harris et al [20], Harris and Rhodes [21], Rhodes and
Treloar [22], and Roy et al [34]. Taken together, our findings
suggest that HCV awareness and prevention interventions may
have weak impact if juggled alongside multiple situated and
competing priorities, and that the impact of HCV prevention
efforts may be enhanced through social intervention approaches
tailored in relation to the situated and pragmatic concerns of
PWID.
Study Limitations
The 95% confidence interval (25%–57%) for the HCV
seropositive prevalence point estimate of 41% from the present
study encompasses the prevalence estimate for both London (56%)
[1], and England as a whole (45%). [1] However, as participation
rates by HCV status could not be determined, the possibility that
potential subjects who were seropositive for HCV would be less
likely to participate in the study could not be established. Also, our
assessment of the HCV status of the participants was limited to the
sensitivity and specificity of the antibody and PCR tests used to
determine HCV status.
Several of the participants who reported having consistently
engaged in protective practices were confirmed as HCV positive,
while others reporting a prolonged history of engaging in risky
practices were confirmed as HCV negative. As study participants
had lengthy injection careers an occasional, or atypical, change in
injection behaviour could have resulted in HCV infection. These
lapses may not have been reported as they may not have been
conscious lapses, they may not have assumed much significance, or
they may simply have been forgotten. Though the methodology
used for this study was intended to minimise recall bias it is entirely
possible that, owing to the sheer number of injection experiences
in a participant’s injecting career, a few deviations may not have
assumed much importance. It is also worth noting that all
interview narratives are inevitably shaped by their social contexts,
in which participants frame their accounts in light of perceived
norms, including in relation to hygiene, personal responsibility,
and safety. [35,36] Furthermore, as participants were notified of
the results of their serological screening following their initial
interview, it is possible that confirmation of serostaus influenced
participants’ perceptions of risk and may have thus influenced
their responses during subsequent interviews. With respect to those
who consistently engaged in risky practices, yet were found to be
HCV negative, the possibility of cell-mediated immunity or of
spontaneous seroreversion could not be ruled out. [37,38].
Finally, as participants were recruited from HCV testing and
screening services it is possible that the sample is not generalisable
to the population, as PWID who avail themselves of these services
may not share the risk profile of users who choose not to. Previous
research among PWID in Australia [39,40], Canada [41], and
Europe [42] have suggested that the risk profile of PWID differs
when comparing catchment facilities.
Conclusion
In this sample of 37 PWID, protective practices had no obvious
association with the outcome of interest (HCV status). Further-
more, avoiding HCV specifically was relatively infrequently cited
as a motivation for engaging in protective practices. This
highlights the need to consider how practices not directly related
to viral avoidance may nonetheless have prevention potential, and
the role of qualitative life history approaches in enabling these to
become visible. Since these practices may also be effective in
avoiding infection with HIV, or other blood-borne viruses, it is
important to consider the relative importance of different
motivations, with respect to specific practices, in order to
formulate harm reduction interventions which appeal to the most
pressing concerns of PWID.
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